Epcoritamab in previously treated WM

Recruiting
Written By Sustainable Digital

First trial using an anti-CD20 bispecific antibody for WM in the world

Sites: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, UNC Medical Center. Pending at UT Southwestern, City of Hope

Accrual status: 5 of 20 patients

Sustainable Digital

Digital Communication services, including website design, search engine optimization, social media, and content creation for nonprofit organizations, consultants, and creative entrepreneurs.

http://www.sustainabledigital.com
Previous

Zanubrutinib, Bendamustine, and Rituximab (ZEBRA) in previously untreated WM
Next

Pirtobrutinib, Venetoclax, and Rituximab (PROVEN) in previously untreated WM